Imugene logo

Imugene(OTC) IUGNF

Market Cap$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-82%
5 Year-100%
1 Year-90%
1 Month-45%
$0.03
-30.56%
-0.01Today
Imugene last closing stock price
MetricPriceDate
Last closeUSD 0.032026-10-08
Imugene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.14%USD 0.032026-10-01
1 month-45.45%USD 0.062026-09-08
3 month-60%USD 0.082026-07-10
Year to date-88.46%USD 0.262025-12-31
1 year-90%USD 0.302025-10-08
3 year-97.06%USD 1.022023-10-09
5 year-99.73%USD 11.112021-10-08
Since inception-82.35%USD 0.172019-07-05

Imugene Financials at a Glance

Market Cap

$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$4.40M

Net Income (TTM)

-A$174.25M

EPS (TTM)

-$0.22

P/E Ratio

-0.14

Dividend

$0.00

Beta (Volatility)

-2.54 (Low)

Price

$0.03

Volume

793

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.04

52-Week Range

$0.02 - $0.31

Estimated Earnings Date

Mar 3, 2027

IUGNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imugene

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Leslie Chong

Website

imugene.com

Headquarters

Sydney, NSW 2000, AU

IUGNF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-414.10%

Return on Capital

-489.63%

Return on Assets

-457.36%

Earnings Yield

-7.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

548.90M

Volume

793

Avg. Volume

22.31K

Financials (TTM)

Gross Profit

-A$2.44M

Operating Income

-A$144.42M

EBITDA

-A$138.92M

Operating Cash Flow

-A$120.39M

Capital Expenditure

-A$7.55M

Free Cash Flow

-A$127.94M

Cash & ST Invst.

A$2.63M

Total Debt

A$6.29M

Imugene Performance Analysis

Imugene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Imugene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31140.6%
Q42025-06-30149.5%
Q22025-12-31-100.0%
Q42026-06-30N/A
Imugene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.14-16.7%
20242024-06-30AUD -0.47240.8%
20252025-06-30AUD -0.14-70.3%
20262026-06-30AUD -0.2256.4%
Imugene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3142.1%
Q42025-06-3057.2%
Q22025-12-31-38.0%
Q42026-06-30-46.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

+100.0%

Gross Profit

-A$1.63M

+47.2%

Gross Margin

0.00%

N/A

Market Cap

$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.18M

N/A

Employees

14

N/A

Net Income

-A$67.42M

+16.7%

EBITDA

-A$31.44M

+56.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$2.63M

-97.2%

Total Debt

A$6.29M

+306.6%

Accounts Receivable

A$2.37M

-81.2%

Inventory

A$4.40M

+297.9%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$6.29M

+589.3%

Return on Assets

-4.57%

N/A

Return on Invested Capital

-8.16%

N/A

Free Cash Flow

-A$18.86M

+59.8%

Operating Cash Flow

-A$18.86M

+61.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VSBCVitaSpring Biomedical Co. Ltd.
$0.01+0.00%
HSCHFH-Source Holdings Ltd.
$0.00+0.00%
BSEMBioStem Technologies, Inc.
$2.64+10.46%
PRNAFAlterity Therapeutics Limited
$0.40+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$142.52-10.31%
TQQQProShares Trust - ProShares UltraPro Qqq
$80.23-4.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.37+4.05%

Questions About IUGNF

What is the current price of Imugene?

Imugene is trading at $0.03 per share.

What is the 52-week range for Imugene?

Over the past 52 weeks, Imugene has traded between $0.02 and $0.31.

How much debt does Imugene have?

As of the most recent reporting period, Imugene reported total debt of A$4.36M.

How much cash does Imugene have on hand?

Imugene reported A$1.82M in cash and cash equivalents in its most recent financial results.

What is Imugene’s dividend yield?

Imugene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services